HealthdirectFree Australian health advice you can count on.

( ARTG ) Severe eosinophilic asthma,NUCALA is indicated as an add-on treatment for severe eosinophilic asthma in patients aged 12 years and over (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical Trials).,Chronic Obstructive Pulmonary Disease (COPD),NUCALA is indicated as an add-on maintenance treatment for adult patients with uncontrolled chronic obstructive pulmonary dise‍‍‍‍‍‍​​​‍​​​​​​ase (COPD) with raised blood eosinophils on stable inhaler triple therapy (or, where clinically required, an equivalent regimen) (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical Trials).,Chronic Rhinosinusitis with Nasal Polyps (CRSwNP),NUCALA is indicated as add-on treatment in adult patients (18 years and above) with severe chronic rhinosinusitis with nasal polyps (CRSwNP) with an inadequate response to intranasal corticosteroids (see Section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical Trials).,Relapsed or refractory EGPA,NUCALA is indicated as an add-on treatment for relapsing or refractory Eosinophilic Granulomatosis with Polyangiitis (EGPA) in adult patients aged 18 years and over (see section 5.1 PHARMACODYNAMIC PROPERTIES, Clinical Trials).